
-
Spruce Biosciences NASDAQ:SPRB Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS (estimated to be 150,000 to 200,000 patients in the United States).
Location: | Website: www.sprucebiosciences.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-42.98M
Cash
60.06M
Avg Qtr Burn
-11.62M
Short % of Float
1.77%
Insider Ownership
11.57%
Institutional Own.
44.05%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tildacerfont Details Polycystic ovary syndrome | Phase 2 Update | |
Tildacerfont Details Congenital adrenal hyperplasia, Primary biliary cholangitis, Liver disease | Failed Discontinued | |
Tildacerfont Details Congenital adrenal hyperplasia | Failed Discontinued |